Inivata Names New Chief Operations Officer

Cancer genomics company Inivata has appointed a clinical diagnostics veteran as its new chief operations officer.

Cancer genomics company Inivata Ltd. has named Jamie Platt as Chief Operations Officer. Platt will be based at Inivata's CLIA lab in Research Triangle Park, North Carolina and help drive operational activities across the organization in both the UK and the US to accelerate use the company's InVision liquid biopsy platform

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

OneCell Diagnostics’ Mohan Uttarwar Discusses Liquid Biopsy Breakthroughs And The Future Of Precision Oncology

 
• By 

OneCell’s co-founder Uttarwar discusses clinical validation milestones, CLIA certification, and the startup’s strategic roadmap – from hospital partnerships in India to biopharma collaborations in the US.

MedStar Teams Up With Reimagine Care To Extend Cancer Care Into Patients’ Home

 
• By 

Reimagine Care teamed up with MedStar Health to support cancer patients at home via an AI assistant and clinical support. Reimagine Care’s data suggests its platform can save cancer centers up to $1m annually per full-time oncologist panel and reduce ED visits by 30%.

Anglonordic 25: Pictura Bio’s One-Minute Pathogen-Identifying Diagnostic Test

 

“Infectious disease should be treated in the community, not in hospitals,” Alex Batchelor, Pictura Bio CEO, told Medtech Insight at the Anglonordic Life Science Conference on 3 April in London.

OneCell Diagnostics’ Mohan Uttarwar Discusses How AI Helps To Predict Cancer’s Next Move

 
• By 

Part 1 of 2: In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single cell biopsy platform is rewriting the rules of cancer diagnostics – not just identifying cancer at the cellular level but predicting its potential return with unprecedented accuracy. He also shares how the company’s approach leverages single cell biopsy technology and machine learning to spot signs of cancer’s return before it manifests clinically.

More from Medtech Insight

Looking Back Towards The Future

 

As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.

Notified Bodies Warn Of Hurdles In The Way Of Their AI Designations

 

Will challenges in the way of designations of notified bodies that assess AI-enabled medical devices create delays and bottlenecks and slow EU medtech innovation?

Guidance Feedback Highlights Outstanding Questions In AI Development

 
• By 

Many of the hundred-plus commenters to the FDA's draft guidance on AI in medical product regulation said the document was a good start but needed additional clarity and more concrete examples. Stakeholders recommended the inclusion of case studies, metrics, and clearer guidelines to enhance the utility of the guidance, which is seen as a vital step for AI integration in healthcare.